Revium Rx (RVRC) Debt Ratio (2024 - 2026)
Revium Rx's (RVRC) quarterly Debt Ratio came in at 0.0 in Q2 2026, up 16.77% quarter-over-quarter from 0.0 in Q4 2025.
Analysis
Revium Rx (RVRC) Debt Ratio (2024 - 2026) Analysis & Trends
Revium Rx has disclosed Debt Ratio across 3 years of filings, most recently posting 0.0 for Q2 2026.
- In Q2 2026, Debt Ratio changed N/A year-over-year to 0.0; the TTM figure through Jun 2026 stood at 0.0 (changed N/A YoY), while the FY2025 annual figure was 0.0, down 98.87% from the prior year.
- Debt Ratio came in at 0.0 for Q2 2026 at Revium Rx, up from 0.0 in the prior quarter.
- In the past five years, Debt Ratio ranged from a high of 0.01 in Q4 2024 to a low of 0.0 in Q4 2025.
- Average Debt Ratio over 3 years is 0.0, with a median of 0.0 recorded in 2026.
- The largest YoY upside for Debt Ratio was 98.87% in 2025 against a maximum downside of 98.87% in 2025.
- Over 3 years, Debt Ratio stood at 0.01 in 2024, then slumped by 98.87% to 0.0 in 2025, then climbed by 16.77% to 0.0 in 2026.
- Per Business Quant data, the three most recent Debt Ratio figures were 0.0 in Q2 2026, 0.0 in Q4 2025, and 0.01 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 0.66 |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 0.58 |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 0.05 |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 0.05 |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 0.25 |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 0.26 |
| 10 | Revium Rx | 86.84 Mn | 85.34 Mn | - | 0.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.00 |
| Dec 31, 2025 | 0.00 |
| Dec 31, 2024 | 0.01 |